Abstract
BRL 42715, a novel beta-lactamase inhibitor, was evaluated for its capacity to inhibit cephalosporinases. BRL 42715 was effective in potentiating the activity of antibiotics against clinical isolates of Enterobacteriaceae that produced high levels of cephalosporinases. This correlated well with the very low 50% inhibition values (< 0.004 mg/L) of BRL 42715 for cephalosporinases extracted from different species. When compared in vitro to clavulanic acid, sulbactam, and tazobactam, BRL 42715 was the most efficient inhibitor of cephalosporinase.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / pharmacology*
-
Cell Membrane Permeability / physiology
-
Cephalosporinase / biosynthesis
-
Drug Synergism
-
Enterobacteriaceae / drug effects
-
Enterobacteriaceae / enzymology*
-
Enterobacteriaceae / metabolism
-
Lactams*
-
Microbial Sensitivity Tests
-
beta-Lactamase Inhibitors*
-
beta-Lactams*
Substances
-
Anti-Bacterial Agents
-
Lactams
-
beta-Lactamase Inhibitors
-
beta-Lactams
-
C6-(N1-methyl-1,2,3-trazolylmethylene)penem
-
Cephalosporinase